On Thursday, the 17th of October 2019, US-based multinational corporation, Johnson & Johnson, headquartered in New Brunswick, New Jersey, engaged in developing medical devices, pharmaceutical alongside consumer goods, had agreed to a $117 million settlement in a bid to resolve accusations that the company had exercised a deceptive marketing for transvaginal surgical mesh device, widely used in vaginal and uterine prolapse alongside treatment of bladder issues, the US state Attorney General Said.
In point of that, latest J&J settlement on mischievous marketing of its transvaginal surgical mesh device follows a $8 billion in punitive measures over claims on usage of its anti-psychotic drug, Risperdal. Nonetheless, according to Thursday’s (October 17th) ruling, the $117 million settlement would be resolving a number of investigations across the United States which had found that the New Jersey-based conglomerate’s transvaginal mesh devices had violated several consumer protection laws by falsifying the safety and efficacy of the device, while J&J had also failed to disclose the risks associated with the usage of the device.
More importantly, hundreds of complaints were lodged in claims and liabilities against J&J’s transvaginal mesh device, while a number of women had filed that they were injured by J&J’s pelvic mesh device.
Thursday’s (October 17th) settlement would resolve probes and claims launched by 41 US states alongside the District of Columbia.